1 / 42

Ebol a Virus infection

Ebol a Virus infection . Dr Ernet Elienguo,MD Dr Chritin Nyndi,MD EMERGENCY DEPERTMENT. ebol. outline. Background Epidemiology Etiology P a thophysiology Clinical presentation Work up Prognosis Management prevention. background.

chudspeth
Download Presentation

Ebol a Virus infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Ebola Virus infection Dr ErnetElienguo,MD Dr ChritinNyndi,MD EMERGENCY DEPERTMENT

  2. ebol

  3. outline • Background • Epidemiology • Etiology • Pathophysiology • Clinical presentation • Work up • Prognosis • Management • prevention

  4. background • Ebola virus disease (EVD), is a severe, often fatal illness in humans. • EVD outbreaks have a case fatality rate of up to 90%. • EVD outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests. • The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. • Fruit bats of the Pteropodidae family natural host of the Ebola virus. • Severely ill patients require intensive supportive care. No licensed specific treatment or vaccine is available for use in people or animals.

  5. background • Ebola first appeared in 1976 in 2 simultaneously outbreak in NZr Sudan and Yambuku DRC the latter in village situated near Ebola river in which the disease take it name

  6. background • Ebola virus is one of at least 30 known viruses capable of causing viral hemorrhagic fever syndrome • The genus Ebolavirus is currently classified into 5 separate species: Sudan ebolavirus, Zaire ebolavirus, Tai Forest (Ivory Coast) ebolavirus, Reston ebolavirus, and Bundibugyo ebolavirus.

  7. background • Primary exposure • Secondary exposure

  8. epidemiology • Ebola and Marburg viruses are responsible for well-documented outbreaks of severe human hemorrhagic fever, with resultant case mortalities ranging from 23% for Marburg virus to 89% for Ebola virus in which more than one case occurred

  9. epidemiology • As of July 23, 2014, 1201 total suspected or confirmed cases (814 laboratory-confirmed) had been reported in these countries, resulting in 672 deaths

  10. outbreak

  11. Outbreaks

  12. Disease update • New cases and deaths attributable to EVD continue to be reported by the Ministries of Health in Guinea, Liberia, Nigeria, and Sierra Leone. • Between 7 and 9 August 2014, 69 new cases (laboratory-confirmed, probable, and suspect cases) of EVD and 52 deaths were reported from the four countries as follows: • Guinea, 11 new cases and 6 deaths; Liberia, 45 new cases and 29 deaths; Nigeria, 0 new cases and 0 deaths; and Sierra Leone, 13 new cases and 17 deaths.

  13. The current (2014) Ebola virus outbreak is significant and primarily involves 3 African countries—Guinea, Liberia, and Sierra Leone

  14. Ep…. • Age-related demographics • In the 1995 outbreak in Kikwit, DRC, infection rates were significantly lower in children than in adults • Children re less likely to get into contacts . Sex-related demographics • Ebola virus infection has no sexual predilection • Men more likely to get primary exposure while oman more likely to secondary exposure

  15. Race-related demographics • Black • No racil predilection

  16. prognosis' • The overall prognosis for patients with Ebola poor.

  17. prognosis • High mortality rte except for reton ebolaviru • The most highly lethal Ebolavirus species is Zaire ebolavirus, which has been reported to have a mortality rate as high as 89%. • Sudan ebolavirus also has high reported mortality, ranging from 41% to 65%.

  18. clinical presentation • To type of expore • Primary exposure • Secondary exposure

  19. Clinical presentation

  20. Clinical presentation • Mode of tranmiion • Not entirely clear but thought to firt trnmitted to initial peron by animal body fluid or blood or by contaminated medical equipment • airbone tranmiion ha not being documented but they re however infectious breathable • Bt being identified natural reservoir

  21. Clinical… • Secondary exposure refers to human-to-human or primate-to-human exposures. • In each major outbreak, medical personnel or family members who cared for patients or those who prepared deceased patients for burial were at very high risk

  22. Clinical coure • Incubation period range from 2 to 21 day

  23. Cliniclcoure • Severe headache (50%-74%) • arthralgias or myalgias (50%-79%), • fever with or without chills (95%), • anorexia (45%), • asthenia (85%-95%) occur early in the disease

  24. Gastrointestinal (GI) symptoms, • abdominal pain (65%), • nausea and vomiting (68%-73%) • diarrhea (85%), • conjunctivitis (45%), • odynophagia or dysphasia (57%), • bleeding from multiple sites in the GI tract. Bleeding from mucous membranes and puncture sites is reported in 40%-50% of patients

  25. Clinicl coure • A mucopupular rah 15 • Tackpnea i ingle mot discrimination betn survivors n non survivors

  26. etilogy • The known members of the family Filoviridae are the genera Ebolavirus (Ebola virus) and Marburgvirus (Marburg virus). • Ebolavirus is classified into the following 5 separate species: • Sudan ebolavirus • Zaire ebolavirus • Tai Forest ebolavirus (formerly and perhaps still more commonly Ivory Coast ebolavirus or Côte d’Ivoire ebolavirus) • Reston ebolavirus • Bundibugyo ebolavirus

  27. pathophyilogy

  28. Work up • Other diseases that should be ruled out before a diagnosis of EVD can be made include: • malaria, typhoid fever, shigellosis, cholera, leptospirosis, plague, rickettsiosis, relapsing fever, meningitis, hepatitis and other viral hemorrhagic fever

  29. workups • Basic blood tests • CBC(thrombocytopenia, leucopenia, and a pronounced lymphopenia) • BIOCHEMITRY(elevations in AT ALAT) • Coagulopthy • Serum creatine and urea • Serum electrolyte

  30. Workup • Definitive diagnosis rests on isolation of the virus by means of tissue culture or reverse-transcription polymerase chain reaction (RT-PCR) assay. • However, isolation of Ebola virus in tissue culture is a high-risk procedure that can be performed safely only in a few high-containment laboratories throughout the world.

  31. Work up

  32. Work up • Serologic testing for antibody and antigen • the immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) tests may be useful in the diagnosis of Ebola virus infection • The indirect fluorescence antibody test (IFAT) • IgG-capture ELISA uses detergent-extracted viral antigens to detect IgG anti-Ebola antibodies

  33. Work up • Histology • endothelial cells, • hepatocytes, and • mononuclear phagocytes • Viral replication is associated with extensive focal necrosis and is most severe in the liver, spleen, lymph nodes, kidney, lung, and gonads.

  34. Treatments and managements • Currently, no specific therapy is available that has demonstrated efficacy in the treatment of Ebola hemorrhagic fever. • There are no commercially available Ebola vaccines. • However, a recombinant human monoclonal antibody directed against the envelope GP of Ebola has been demonstrated to possess neutralizing activity

  35. Support care • Supportive therapy with attention to • intravascular volume • Electrolytes • Nutrition • Intravascular volume repletion is one of the most important supportive measures.

  36. Pharmacology agent • To drug re currently being approved to be used • MAPP • TKM-Ebola

  37. Diet

  38. prevention • Work continues on a vaccine for Ebola virus infection in primates • This work indicates that primates can be vaccinated against Ebola virus and can develop both a cell-mediated response (thought to be a result of the DNA vaccine) and a humoral antibody response (thought to be a result of the recombinant adenoviral vaccine)

  39. prevention • Infection control inside and outside of medical facilities relies on barrier protection using • double gloves, • fluid-impermeable gowns, • face shields with eye protection, • coverings for legs and shoes.

More Related